Biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving hearing loss.


Latest news

  • 29 July 2020

    Sensorion appoints five renowned experts to its Scientific Advisory Board. Read

  • 20 July 2020

    Sensorion will present at the Bioprocessing Summit Europe virtual conference on July 21-23, 2020. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has one clinical stage drug candidate for sudden sensorineural hearing loss, two preclinical gene therapy programs and a cutting-edge inner ear R&D platform. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more